First Wave BioPharma to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2023”
BOCA RATON, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc. (NASDAQ: FWBI)…
Year: 2022
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
AUSTIN, Texas, Dec. 12, 2022 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical…
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022
Presentation shows the therapeutic potential of combining iPSC-derived CAR NK cells and NK cell engagers…
Genomic Biopharma and patient advocacy organization POIC e dintorni APS partner to offer whole genome sequencing to bring better treatments and cures to those living with gastrointestinal diseases
L’AQUILA, Italy, Dec. 12, 2022 (GLOBE NEWSWIRE) — Genomic Biopharma Inc., a genomic medicine-based drug…
BiondVax Regains Nasdaq Compliance
JERUSALEM, Dec. 12, 2022 (GLOBE NEWSWIRE) — via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV)…
Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIA
All patients achieved sustained engraftment and supraphysiological SGSH enzyme levels with median 1.5 years follow-up…
IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100
Results from the first cohort of patients with hematological malignancies show patients remained progression free;…
Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration
WILMETTE, Ill, Dec. 12, 2022 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical…
Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Humanized anti-SARS-CoV-2 Monoclonal Antibodies from Curia Global, Inc.
Immunocompromised Individuals, Including Organ Transplant Recipients, are at Increased Risk of Severe COVID-19 and Poor…
Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis
NDA based on two positive randomized, double-blinded, placebo-controlled trials which enrolled a total of 678…
PolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
Meeting Scheduled for January 2023 PolyPid Recently Provided FDA with Currently Available Data from Completed…
Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
Los Gatos, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a…
TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022
Poster presents Phase 1 trial design and translational assays to generate early evidence of biological…
Castellum Announces That It Is One Of The Winners Of The $900 Million Air Force Architecture And Integration Directorate Multiple Award Indefinite Delivery/Indefinite Quantity Contract (AFLCMC/XA) (MAC IDIQ)
Castellum Announces That It Is One of The Winners Of The $900 million Air Force…
Eagle Pharmaceuticals Reaches Settlement Agreement with Accord Healthcare, Inc. Related to BENDEKA® (bendamustine hydrochloride)
WOODCLIFF LAKE, N.J., Dec. 12, 2022 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”…
Societal CDMO Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
EXTON, Pa., Dec. 12, 2022 (GLOBE NEWSWIRE) — Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a…
Societal CDMO Advances Multi-Step Strategy to Recast Capital Structure and Strengthen Balance Sheet
Signs Agreement for $39 Million Sale and Leaseback Transaction with Tenet Equity; Proceeds to be…
Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.
SAN FRANCISCO, Dec. 12, 2022 (GLOBE NEWSWIRE) — Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or…
Aptose Biosciences Establishes New At-The-Market Facility
SAN DIEGO and TORONTO, Dec. 12, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or…
Kubient Receives Patent for KAI Solution
Kubient Becomes One of the Few Adtech Companies to Receive a Patent on Fraud Prevention in…